• June 16-19, 2025
  • Boston Convention & Exhibition Center

Sessions

Loading

The Bad and the Ugly: Unpacking Repercussions of the Medicaid Drug Rebate Program Rule

Tuesday, June 04, 2024
Breakout Session
Value‚ Patient Access and Reimbursement
29AB
In May of 2023, the Centers for Medicare & Medicaid Services (CMS) proposed to upend more than three decades of historical precedent by rewriting the rules of the road for Medicaid drug rebate calculations. This sweeping rule fundamentally shifts the reimbursement structure of drugs, placing a substantial burden on manufacturers and putting patient access at risk. This session will shed light on the current healthcare landscape one year after the rule was initially proposed and the industry’s ongoing efforts to mitigate the rule’s negative impacts. Provisions that will be covered include the best price stacking proposal, the new definition of covered outpatient drug, the drug price verification survey, and other patient access considerations.
Moderator
Patrick Plues
SVP, State Government Relations
Biotechnology Innovation Organization
Speakers
Melanie Lendnal
Senior Vice President of Policy & Advocacy
ALS Association
Matt Salo
CEO
Salo Health Strategies
Alice Valder Curran, JD
Partner
Hogan Lovells
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS